Abstract
Antibody therapy has become standard of care for adult B cell lymphoma patients. It is a potentially less toxic and more targeted approach for lymphoma therapy and should therefore be applied to treat pediatric B cell lymphoma patients as well. In pediatric lymphoma patients, however, clinical experience with monoclonal antibodies is very limited. This is in part due to smaller patient numbers and very good outcome with conventional chemotherapy. In addition, pediatric patient and lymphoma biology differ significantly from that found in adults often precluding extrapolation of the adult experience to children. This review focuses on targeting pediatric B cell lymphoma with monoclonal antibody therapy. The special characteristics of B cell lymphomas found in children are reviewed and six potential new lymphoma target antigens are discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 2158-2163 |
| Number of pages | 6 |
| Journal | Pediatric Blood and Cancer |
| Volume | 61 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 1 Dec 2014 |
| Externally published | Yes |
Keywords
- Burkitt lymphoma
- Cancer immunotherapy
- Diffuse large B cell lymphoma
- Hodgkin lymphoma
- Monoclonal antibodies
- Pediatric cancer